Health.amReferences
1. Perti A, Kantarjin HM. Management of adult acute lymphocytic leukemia: present issues and key challenges. J Clin Oncol. 1994;12:1312-1322.
2. Hoelzer DF. Therapy of the newly diagnosed adult with acute lymphoblastic leukemia. Hematol Oncol Clin N Am. 1993;7:139-160.
3. Mayer RJ, Davis RB, Schiffer CA, et al. Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B. N Engl J Med. 1994;331(14):896-903.
4. Larson RA, Dodge RK, Linker CA, et al. A randomized controlled trial of filgrastim during remission induction and consolidation chemotherapy for adults with acute lymphoblastic leukemia: CALGB study 9111. Blood. 1998;92(5):1556-1564.
5. Appelbaum FR, Baer MR, Carabasi MH, et al. National Comprehensive Cancer Network. NCCN Practice Guidelines for Acute Myelogenous Leukemia. Oncology (Hunting). 2000;14(11A):53-61.
6. Tallman MS, Rowe JM. Acute promyelocytic leukemia: a paradigm for differentiation therapy with retinoic acid. Blood Rev. 1994;8:70-78.
7. Harris NL, Jaffe ES, Diebold J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting, Airlie House, Virginia, November 1997. J Clin Oncol. 1999;17(12):3835-3849.
8. Greenberg P, Cox C, Le Beau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89:2079.
9. Kantarjian HM, Deisseroth A, Kurzrock R, et al. Chronic myelogenous leukemia: a concise update. Blood. 1993;82:691-703.
10. Tura S, Baccarani M, Zuffa E, et al. Interferon alpha-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. N Engl J Med. 1994;330:820-825.
11. Druker BJ, Sawyers CL, Kantarjian H, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med. 2001;344(14):1038-1042.
12. Berk PD, Wasserman LR, Fruchtman SM, et al. Treatment of polycythemia vera: a summary of trials conducted by the Polycythemia Vera Study Group. In: Wasserman LR, Berk PD, Berlin NI, eds. Polycythemia Vera and the Myeloproliferative Disorders. Philadelphia: Saunders; 1995:166-194.
13. Sacchi S, Leoni P, Riccardi A, et al. A prospective comparison between treatment with phlebotomy alone and with interferon-alpha in patients with polycythemia vera. Ann Hematol. 1994;68:247-250.
14. Benblassat J, Gilon D, Penchas S. The choice between splenectomy and medical treatment in patients with advanced agnogenic myeloid metaplasia. Am J Hematol. 1990;33:128-135.
15. Oscier DG. Cytogenetic and molecular abnormalities in chronic lymphocytic leukemia. Blood Rev. 1994;8:88-97.
16. Rai KR, Peterson BL, Appelbaum FR, et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med. 2000;343(24):1750- 1757.
17. Flynn JM, Byrd JC. Campath-1H monoclonal antibody therapy. Curr Opin Oncol. 2000;12(6):574-581.
18. Cooperative Group for the Study of Immunoglobulin in Chronic Lymphocytic Leukemia. Intravenous immunoglobulin for the prevention of infection in chronic lymphocytic leukemia. A randomized controlled clinical trial. N Engl J Med. 1988;319:902.
19. Smalley RV, Conners J, Tuttle RL, et al. Splenectomy vs. alpha interferon: a randomized study in patients with previously untreated hairy cell leukemia. Am J Hematol. 1992;41:13-18.
20. Saven A, Piro L. Newer purine analogues for the treatment of hairy-cell leukemia. N Engl J Med. 1994;330:691-697.
21. Crawford J, Eye MK, Cohen HJ. Evaluation of monoclonal gammopathies in the "well" elderly. Am J Med. 1987;82:39- 45.
22. Kyle RA. Monoclonal gammopathy of undetermined significance. Curr Top Microbiol Immunol. 1996;210:375.
23. Kyle RA. Current concepts on monoclonal gammopathies. Aust N Z J Med. 1992;22:291-302.
24. Alexanian R, Dimopoulos M. The treatment of multiple myeloma. N Engl J Med. 1994;330:484-489.
25. Attal M, Harousseau JL, Stoppa AM, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Engl J Med. 1996;335:91-97.
26. Siegel DS, Desikan KR, Mehta J, et al. Age is not a prognostic variable with autotransplants for multiple myeloma. Blood. 1999;93:51-54.
27. Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidmide in refractory multiple myeloma. N Engl J Med. 1999;341:1565-1571.
28. Rajkumar S, Fonseca R, Dispenzieri A, et al. Thalidomide in the treatment of relapsed mutliple myeloma. Mayo Clin Proc. 2000;75:897-901.
29. Sonneveld P, Durrie BGM, Lokhorst HM, et al. Modulation of multidrug-resistant multiple myeloma by cyclosporine. Lancet. 1992;340:255-259.
30. Ludwig H, Fritz E, Kotzmann H, et al. Erythropoietin treatment of anemia associated with multiple myeloma. N Engl J Med. 1990;322:1693-1699.
31. Crawford J, Cox EB, Cohen HJ, Evaluation of hyperviscosity in monoclonal gammopathies. Am J Med. 1985;79:13.
32. Gertz MA, Kyle RA, Greipp PR. Response rates and survival in primary systemic amyloidosis. Blood. 1991;77:257- 262.
33. Weisenburger DD. Epidemiology of non-Hodgkin's lymphoma: recent findings regarding an emerging epidemic. Ann Oncol. 1994;5(suppl 1):19-24.
34. Gaidano G, Dalla-Favera R. Biologic and molecular characterization of non-Hodgkin's lymphoma. Curr Opin Oncol. 1993;5:776-784.
35. Young RC, Longo DL, Glatsein E, et al. The treatment of indolent lymphomas: watchful waiting vs. aggressive combined modality treatment. Semin Hematol. 1988;25:11.
36. McLaughlin P, Grillo-Lopez AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to four dose treatment program. J Clin Oncol. 1998;16:2825- 2833.
37. Hainsworth JD, Burris HA III, Morrissey LH, et al. Ritux-imab monoclonal antibody as initial systemic therapy for patients with low-grade non-Hodgkin's lymphoma. Blood. 2000;95:3052-3056.
38. Czuczman MS, Grillo-Lopez AJ, White CA, et al. Treat-ment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol. 1999;17:268- 276.
39. Shipp MA. Prognostic factors in aggressive non-Hodgkin's lymphoma: who has "high-risk" disease?Blood. 1994;83:1165-1173.
40. Dixon DO, Neilan B, Jones SE, et al. Effect of age on therapeutic outcome in advanced diffuse histiocytic lymphoma: the Southwest Oncology Group experience. J Clin Oncol. 1986;4:295-305.
41. Sonneveld P, de Ridder M, van der Lelie H, et al. Comparison of doxorubicin and mitoxantrone in the treatment of elderly patients with advanced diffuse non-Hodgkin's lymphoma using CHOP versus CNOP chemotherapy. J Clin Oncol. 1995;13:2530-2539.
42. Coiffier B, Lepage E, Herbrecht R, et al. Mabthera (Rituximab) plus CHOP is superior to CHOP alone in elderly patients with diffuse large B-cell lymphoma (DLCL): interim results of a randomized GELA trial. Blood. 2000;96:abstract950.
43. Kaufman D, Longo DL. Hodgkin's disease. Clin Rev Oncol Hematol. 1992;13:135-187.
44. Canellos GP, Anderson JR, Propert KJ, et al. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med. 1992;327:1478-1484.
45. Mir R, Anderson J, Strauchen J, et al. Hodgkin's disease in patients 60 years of age or older. Cancer. 1993;71:1857- 1866.
